Moderna and Merck Report Positive Phase 3 Results for Personalized Melanoma Vaccine
Moderna and Merck announced positive interim results from a Phase 3 trial of their personalized mRNA cancer vaccine, Intismeran, combined with Merck's immunotherapy Keytruda, for high-risk melanoma patients. The treatment met primary and secondary goals by significantly reducing cancer recurrence and spread compared to Keytruda alone. The study is ongoing, with overall survival data pending. Both companies plan to present detailed results at an upcoming medical meeting and anticipate regulatory discussions soon. Moderna and Merck stocks rose sharply following the news.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (76/100). Lens Score 40/100.
Outlets measured: moneycontrol, mint. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
mint broke this story on 19 Aug, 01:04 pm. Other outlets followed.